Phase II Open Label Study of the oral VEGF-Receptor inhibitor PTK787/ZK222584 (Vatalanib) in Adult Patients with Refractory or Relapsed Diffuse Large B Cell Lymphoma

PTK787/ZK222584 (Vatalanib), an orally active inhibitor of vascular endothelial growth factor receptors (VEGF-Rs), was evaluated in this phase II study of 20 patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Patients received once daily PTK787/ZK222584 at a target dose of 1250...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Brander, DM, Rizzieri, DA, Gockerman, JP, Diehl, LF, Shea, TC, DeCastro, CM, Moore, JO, Beaven, AW.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2013
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3990732/
https://ncbi.nlm.nih.gov/pubmed/23488610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2013.784969
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items